Adaptimmune Therapeutics Plc Stock Price, News & Analysis

Adaptimmune Therapeutics presented data from its Phase 1 trial of ADP-A2AFP targeting alpha-fetoprotein (AFP) at the International Liver Congress. One out of four patients treated with five billion or more SPEAR T-cells achieved a complete response, demonstrating acceptable safety despite subsequent disease progression. Notably, a total of nine patients have been treated, with ongoing evaluations of the therapy's effectiveness. Results support further development of ADP-A2AFP for hepatocellular carcinoma (HCC), as the company continues patient enrollment in the expansion phase.

Adaptimmune Therapeutics (Nasdaq: ADAP) reported Q2 2020 financial results, noting significant progress with its ADP-A2M4 therapy for sarcoma. The company raised approximately $244 million through a public offering, ensuring funding into 2022. They received PRIME regulatory support from the EMA for ADP-A2M4 targeting synovial sarcoma and reported responses in multiple solid tumor types during ASCO. The net loss for Q2 was $29.9 million, an improvement over last year's loss of $41.1 million. The company plans to launch ADP-A2M4 in the US in 2022 and continues to advance its clinical trials.

Adaptimmune Therapeutics (Nasdaq: ADAP) announced that the European Medicines Agency (EMA) has granted access to the PRIME initiative for ADP-A2M4, aimed at treating synovial sarcoma. This designation provides enhanced regulatory support to address unmet medical needs. The decision is based on promising Phase 1 trial data showing efficacy and tolerable safety. Adaptimmune has initiated the SPEARHEAD-1 trial for ADP-A2M4, targeting advanced synovial sarcoma and myxoid liposarcoma. The company has also received Orphan Drug Designation from the FDA for related treatments.

Adaptimmune Therapeutics plc (Nasdaq: ADAP) will announce its Q2 2020 financial results and business update on August 6, 2020, prior to U.S. market opening. Following this, a live teleconference and webcast will be hosted at 8:00 a.m. EDT. Investors can access the event via the company's website. Adaptimmune focuses on developing cancer immunotherapy products, utilizing its unique SPEAR® T-cell platform to target solid tumors. The press release also includes forward-looking statements regarding risks and uncertainties that may affect the company's results.

Adaptimmune Therapeutics plc (Nasdaq: ADAP) has successfully closed its underwritten public offering of 23,575,000 American Depositary Shares (ADSs) at $11.00 each, raising net proceeds of approximately $242.8 million. The offering included 3,075,000 ADSs from underwriters' full exercise of their option to purchase additional shares. The funds will be utilized to advance clinical trials of their immunotherapies and for general corporate purposes. Cowen and SVB Leerink were joint book-running managers for this offering.

Adaptimmune Therapeutics plc (Nasdaq: ADAP) has priced an underwritten public offering of 20.5 million American Depositary Shares (ADSs) at $11.00 each, aiming for a gross size of $225.5 million. The offering will support the advancement of Adaptimmune’s immunotherapy development and general corporate purposes. Underwriters have a 30-day option to purchase an additional 3.075 million ADSs. The offering is expected to close around June 4, 2020, pending customary conditions. Cowen and SVB Leerink are jointly managing the offering.

Adaptimmune Therapeutics (Nasdaq: ADAP) reported significant developments in its latest press release. The company received a $50 million upfront payment from Astellas and completed an offering generating approximately $90 million. Financial guidance confirmed that funds will last into 2H 2021. The EU granted Orphan Drug Designation for ADP-A2M4, enhancing its position alongside existing US designations. Upcoming presentations scheduled for major scientific meetings will showcase data on ADP-A2M4 and other programs. The company's net loss for Q1 2020 was $28.2 million.

Adaptimmune Therapeutics (Nasdaq: ADAP) presented significant advancements in its allogeneic T-cell therapy platform at the ASGCT Annual meeting. The company has successfully engineered T-cells from human induced pluripotent stem cells (hiPSCs) that can target and kill MAGE-A4+ cancer cells in vitro. A milestone was achieved with the editing of T-cell receptor expression into hiPSCs' genome, which is crucial for creating large banks of functional T-cells. These developments mark essential progress toward potential clinical applications of Adaptimmune's proprietary therapies.